162607-18-3 Usage
Description
5-Chlorothiophene-2-boronic acid is an organic compound with the chemical formula C4H4BClS. It is an off-white or beige to pale green or brown powder, which is a useful reagent in the field of organic synthesis.
Uses
Used in Pharmaceutical Industry:
5-Chlorothiophene-2-boronic acid is used as a reagent for the Suzuki-Miyaura cross-coupling reaction of arylboronic acids with bromoquinoline. This reaction is significant in the synthesis of various pharmaceutical compounds, as it allows for the formation of carbon-carbon bonds, which are essential in constructing complex molecular structures.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-Chlorothiophene-2-boronic acid serves as a valuable building block for the creation of a wide range of organic molecules. Its unique structure and reactivity make it a versatile compound for use in the development of new materials and compounds with potential applications in various industries.
Used in Research and Development:
5-Chlorothiophene-2-boronic acid is also utilized in research and development laboratories for the exploration of new synthetic pathways and the study of reaction mechanisms. Its involvement in the Suzuki-Miyaura cross-coupling reaction makes it an important tool for understanding the underlying principles of this widely used synthetic method.
Check Digit Verification of cas no
The CAS Registry Mumber 162607-18-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,2,6,0 and 7 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 162607-18:
(8*1)+(7*6)+(6*2)+(5*6)+(4*0)+(3*7)+(2*1)+(1*8)=123
123 % 10 = 3
So 162607-18-3 is a valid CAS Registry Number.
InChI:InChI=1/C4H4BClO2S/c6-4-2-1-3(9-4)5(7)8/h1-2,7-8H
162607-18-3Relevant articles and documents
NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
-
Page/Page column 83-84, (2020/05/12)
Provided is a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided is a pharmaceutical composition comprising the said compound.
